Summary
Existing technologies permit the detection of changes in neurotransmitter and/or neuroreceptor expression. This may be useful for diagnosis, for monitoring disease progression, and for assessing the pathogenesis of complications associated with long-term treatment. Although the binding of [11C]raclopride to D2 receptors is subject to competition from endogenous dopamine, this can be exploited to estimate changes in synaptic levels of dopamine. Assessment of processes downstream to the receptor will require the development of new approaches.
Keywords
- Positron Emission Tomography
- Multiple System Atrophy
- Dopamine Release
- Endogenous Dopamine
- Raclopride Binding
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Antonini A, Leenders KL, Vontobel P et al (1997a) Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain 120: 2187–2195
Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL (1997b) Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [nC]raclopride. Mov Disord 12: 33–38
Banati RB, Cagnin A, Myers R et al (1999) In vivo detection of activated microglia by [11C]PK11195-PET indicates involvement of the globus pallidum in idiopathic Parkinson’s disease. Parkinsonism Rel Disord 5: S56–S57
Bhaumik S, Gambhir SS (2002) Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA 99: 377–382
Breier A, Su T-P, Saunders R et al (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569–2574
Brooks DJ, Ibanez V, Sawle GV et al (1990a) Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28: 547–555
Brooks DJ, Salmon EP, Mathias CJ et al (1990a) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson’s disease, studied with PET. Brain 113: 1539–1552
Brooks DJ, Ibanez V, Sawle GV et al (1992) Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with nC-raclopride and positron emission tomography. Ann Neurol 31: 184–192
Broussolle E, Lucking CH, Ginovart N, Pollak P, Remy P, Durr A (2000) [18F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations. Neurology 55: 877–879
Burn DJ, Sawle G, Brooks DJ (1994) Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 57: 278–284
Calne DB (1994) Is idiopathic parkinsonism the consequence of an event or a process? Neurology 44: 4–10
de la Fuente-Fernandez R, Lim AS, Sossi V et al (2001a) Apomorphine-induced changes in synaptic dopamine levels: PET evidence for pre-synaptic inhibition. J Cereb Blood Flow Metab 21: 1151–1159
de la Fuente-Fernandez R, Lu JQ, Sossi V et al (2001b) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol 49: 298–303
de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001c) Expectation and dopamine release: mechanism of the placebo effect in parkinson’s disease. Science 293: 1164–1166
de la Fuente-Fernandez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ (2002) Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 136: 359–363
Eidelberg D, Moeller JR, Ishikawa T et al (1995) Early differential diagnosis of Parkinson’s disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 45: 1995–2004
Feigin A, Fukuda M, Dhawan V et al (2001) Metabolic correlates of levodopa response in Parkinson’s disease. Neurology 57: 2083–2088
Fernandez HH, Friedman JH, Fischman AJ, Noto RB, Lannon MC (2001) Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson’s disease? Med Sci Monit 7: 1339–1343
Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES (1987) Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 48: 1077–1082
Freeman TB, Olanow CW, Hauser RA et al (1995) Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson’s disease. Ann Neurol 38: 379–388
Frey KA, Koeppe RA, Kilbourn MR et al (1996) Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol 40: 873–884
Frost JJ, Rosier AJ, Reich SG et al (1993) Positron emission tomographic imaging of the dopamine transporter with nC-WIN 35,428 reveals marked declines in mild Parkinson’s disease. Ann Neurol 34: 423–431
Fukuda M, Mentis M, Ghilardi MF et al (2001) Functional correlates of pallidal stimulation for Parkinson’s disease. Ann Neurol 49: 155–164
Gambhir SS, Bauer E, Black ME et al (2000) A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA 97: 2785–2790
Garnett ES, Firnau G, Nahmias C (1983a) Dopamine visualized in the basal ganglia of living man. Nature 305: 137–138
Garnett S, Firnau G, Nahmias C, Chirakal R (1983b) Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res 280: 169–171
Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW (1986) Dopamine D2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 19: 487–492
Guttman M, Burkholder J, Kish SJ et al (1997) [nC]RTI-32 PET studies of the dopamine transporter in early dopa-nai’ve Parkinson’s disease: implications for the symptomatic threshold. Neurology 48: 1578–1583
Ishikawa T, Dhawan V, Kazumata K et al (1996) Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 37: 1760–1765
Iyer M, Barrio JR, Namavari M et al (2001) 8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSVl-tk reporter gene expression in vivo using PET. J Nucl Med 42: 96–105
Jenkins IH, Fernandez W, Playford ED et al (1992) Impaired activation of the supplementary motor area in Parkinson’s disease is reversed when akinesia is treated with apomorphine. Ann Neurol 32: 749–757
Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286–293
Kishore A, de la Fuente-Fernandez R, Snow BJ, Schulzer M, Mak E, Huser J, Stoessl AJ, Calne DB (1997) Levodopa-induced dyskinesias in idiopathic parkinsonism (IP): a simultaneous PET study of dopamine D1 and D2 receptors. Neurology 48[Suppl 2]: A327
Koepp MJ, Gunn RN, Lawrence AD et al (1998) Evidence for striatal dopamine release during a video game. Nature 393: 266–268
Kordower JH, Freeman TB, Snow BJ et al (1995) Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 332: 1118–1124
Lee CS, Schulzer M, Mak EK et al (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117: 501–507
Lee CS, Samii A, Sossi V et al (2000) In vivo PET evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol 47: 493–503
Lee CS, Schulzer M, Sossi V, Ruth TJ, McKenzie J, de la Fuente-Fernandez R, Holden JE, Calne DB, Stoessl AJ (2001) Duration-dependent striatal dopamine terminal loss in Parkinson disease levels off at different degrees of severity on the two sides; nC-DTBZ PET evidence for the “event” hypothesis. Neurology 56[Suppl 3]: A73–A74
Marek KL, Seibyl JP, Zoghbi SS et al (1996) [123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46: 231–237
Marek K, Seibyl J, Shoulson I et al (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653–1661
McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38: 1285–1291
Nakamura T, Dhawan V, Chaly T et al (2001) Blinded positron emission tomography study of dopamine cell implantation for Parkinson’s disease. Ann Neurol 50:181–187
Pal PK, Leung J, Hedrich K, Samii A, Lieberman A, Nausieda PA, Calne DB, Breakefield XO, Klein C, Stoessl AJ (2002) [18F]-Dopa PET imaging in early stage, non-parkin juvenile Parkinsonism. Mov Disord 17: 789–794
Pate BD, Kawamata T, Yamada T et al (1993) Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34: 331–338
Piccini P, Brooks DJ, Bjorklund A et al (1999) Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat Neurosci 2: 1137–1140
Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ (1992) Impaired mesial frontal and putamen activation in Parkinson’s disease: a positron emission tomography study. Ann Neurol 32: 151–161
Rinne JO, Bergman J, Ruottinen H et al (1999) Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson’s disease. Synapse 31: 119–124
Samii A, Markopoulou K, Wszolek ZK et al (1999) PET studies of parkinsonism associated with mutation in the a-synuclein gene. Neurology 53: 2097–2102
Samuel M, Ceballos-Baumann AO, Turjanski N et al (1997) Pallidotomy in Parkinson’s disease increases supplementary motor area and prefrontal activation during performance of volitional movements: an H2 150 PET study. Brain 120: 1301–1313
Seeman P, Guan HC, Niznik HB (1989) Endogenous dopamine lowers the dopamine D2 receptor density as measured by 3H raclopride: implications for positron emission tomography of the human brain. Synapse 3: 96–97
Shi N, Boado RJ, Pardride WM (2000) Antisense imaging of gene expression in the brain in vivo. Proc Natl Acad Sci USA 97: 14709–14714
Shinotoh H, Inoue O, Hirayama K et al (1993) Dopamine D1 receptors in Parkinson’s disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 56: 467–472
Shoghi-Jadid K, Small GW, Agdeppa ED et al (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10: 24–35
Snow BJ, Tooyama I, McGeer EG et al (1993) Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34: 324–330
Strafella AP, Paus T, Barrett J, Dagher A (2001) Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 21: RC157
Tavitian B, Terrazzino S, Kuhnast B et al (1998) In vivo imaging of oligonucleotide with positron emission tomography. Nat Med 4: 467–471
Tedroff J, Pedersen M, Aquilonius S-M, Hartvig P, Jacobsson G, Langstrom B (1996) Levodopa-induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by [11C]raclopride displacement and PET. Neurology 46: 1430–1436
Turjanski N, Lees AJ, Brooks DJ (1997) In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson’s disease patients with and without dyskinesias. Neurology 49: 717–723
Vanderborght T, Kilbourn M, Desmond T, Kuhl D, Frey K (1995) The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294: 577–583
Volkow ND, Wang G-J, Fowler JS et al (1994) Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 16: 255–262
Wenning G, Odin P, Morrish P et al (1997) Short-and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson’s disease. Ann Neurol 42: 95–107
Whone AL, Remy P, Davis MR, Sabolek M, Nahmias C, Stoessl AJ, Watts RL, Brooks DJ (2002) The REAL-PET study: slower progression in early Parkinson’s disease treated with ropinirole compared with L-dopa. Neurology 58[Suppl 3]: A82–83
Wilson JM, Kish SJ (1996) The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 16: 3507–3510
Yee RE, Irwin I, Milonas C, Stout DB, Huang SC, Shoghi-Jadid K, Satyamurthy N, Delanney LE, Togasaki DM, Farahani KE, Delfani K, Janson AM, Phelps ME, Langston JW, Barrio JR (2001) Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord 16: 838–848
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Wien
About this paper
Cite this paper
Stoessl, A.J., Lee, C.S., de la Fuente-Fernandez, R. (2003). New concepts and tools in imaging for the study of neurodegenerative disease. In: Horowski, R., et al. Advances in Research on Neurodegeneration. Journal of Neural Transmission. Supplementa, vol 65. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0643-3_9
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0643-3_9
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83907-2
Online ISBN: 978-3-7091-0643-3
eBook Packages: Springer Book Archive